Table of Contents
How does siltuximab work?
Siltuximab is in a class of medications called monoclonal antibodies. It works by blocking the action of a natural substance that causes increased growth of lymph cells in people with MCD.
Does Siltuximab cross the blood brain barrier?
If true, siltuximab has the theoretical benefit, unlike tocilizumab, of possibly preventing or mitigating ICANS since it removes IL-6 from circulation and, as a bulky antibody-IL-6 conjugate, prevents it from crossing the blood–brain barrier (BBB).
Is Siltuximab a chemotherapy?
Siltuximab (Sylvant) Chemotherapy Drug Information.
Is Siltuximab an immunotherapy?
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy.
What are the symptoms of Castleman disease?
Signs of multicentric Castleman disease (MCD) include:
- Fever.
- Night sweats.
- Fatigue (extreme tiredness)
- Appetite and weight loss.
- Abnormally large lymph nodes, typically in the neck, armpit, collarbone, and groin.
- Enlarged spleen or liver.
- Anemia (low amount of red blood cells)
What is the brand name for Siltuximab?
Siltuximab
| Monoclonal antibody | |
|---|---|
| Source | Chimeric (mouse/human) |
| Target | IL-6 |
| Clinical data | |
| Trade names | Sylvant |
How do you manage cytokine release syndrome?
The current generally accepted sequence of agents to manage severe or life-threatening CRS include: 1) tocilizumab with or without corticosteroids, 2) high-dose corticosteroids if not already employed, and 3) other agents such as siltuximab or multiple tocilizumab doses.
What is CRS after car T?
Acute anaphylaxis and tumor lysis syndrome (TLS) have occurred following infusion of CAR T cells. The most prominent and well-described toxicity of CAR T cells is cytokine release syndrome (CRS), a constellation of symptoms including fever and hypotension that is caused by cytokines released by the infused T cells.
How much does Siltuximab cost?
At the list price Siltuximab costs $697.70 and $2,790.80 per 100mg and 400mg vial respectively. At the recommended dose of 11 mg/kg IV, and by assuming a mean weight of 70kg siltuximab costs $255.82 per day and $7,163.05 per 28 day cycle.
What does Castleman disease do to the body?
People with Castleman disease have an increased risk of developing cancers including lymphoma (cancer of the lymph system) and Kaposi’s sarcoma (a cancerous skin tumor). Some people with MCD develop infections that can damage organs and be life-threatening if they are not treated.
What causes Castleman disease?
It’s not clear what causes Castleman disease. However, infection by a virus called human herpesvirus 8 (HHV-8) is associated with multicentric Castleman disease. The HHV-8 virus has also been linked to the development of Kaposi’s sarcoma, a cancerous tumor that can be a complication of HIV/AIDS.
How do you pronounce Siltuximab?
Pronunciation : Sil-TUX- i-mab.
How does Siltuximab work?
Siltuximab is a chimeric monoclonal antibody that binds to interleukin-6 (IL-6), preventing binding to soluble and membrane bound interleukin-6 receptors. Siltuximab interferes with IL-6 mediated growth of B-lymphocytes and plasma cells, secretion of vascular endothelial growth factor ( VEGF) and autoimmune phenomena.
What is the indication of siltuximab for the treatment of Castleman’s disease?
Siltuximab is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
How should co-administration of siltuximab and CYP450 substrates be monitored?
Co-administration of siltuximab and CYP450 substrates with narrow therapeutic index such as warfarin, ciclosporin or theophylline should be closely monitored. Siltuximab is a chimeric monoclonal antibody that binds to interleukin-6 (IL-6), preventing binding to soluble and membrane bound interleukin-6 receptors.
What are the contraindications for Siltuximab?
Siltuximab may lower resistance to infections and should not be administered to patients with severe infections. Siltuximab should be discontinued in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions or cytokine release syndromes.